RxDoctor Payments Data

Kathryn Wingate

Nurse Practitioner · Eau Claire, WINPI 1265915250

Payments from drug & device makers

$1,206in general payments, 2019–2025

Across 55 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$309
  • Teva Pharmaceuticals USA, Inc.$216
  • Otsuka America Pharmaceutical, Inc.$205
  • Alkermes, Inc.$125
  • Lundbeck LLC$103
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$71
  • plus $177 from 6 others

What the payments were for

  • Food & beverage$1,206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,206 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$27,277
Medicare patients
55
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$179,262
VraylarCariprazine Hcl14$19,860
Lurasidone Hcl32$6,811
TrintellixVortioxetine Hydrobromide14$6,742
Aripiprazole65$3,621
Vilazodone Hcl33$2,908
Desvenlafaxine Succinate ErDesvenlafaxine Succinate46$2,618
Divalproex Sodium ErDivalproex Sodium29$2,591
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine51$2,171
Quetiapine Fumarate196$2,122
Atomoxetine Hcl21$1,705
Bupropion XlBupropion Hcl103$1,677
Clozapine26$1,606
Ziprasidone Hcl45$1,563
Buspirone Hcl105$1,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$309$179,26221 claims
AbbVieVraylar$35$19,86014 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$40$6,74214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →